Eli Lilly’s weight-loss therapy Mounjaro became India’s top-selling drug by value in October, data showed on Friday, overtaking GSK’s widely used antibiotic Augmentin, as demand surges in the world’s most populous nation.

The US drugmaker’s popular injectable therapy raked in ₹100 crore ($11.38 million) in October, research firm Pharmarack said. That outpaced Augmentin sales of ₹80 crore last month.

By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of Mounjaro, which is sold at a much higher price point.

The news comes as India becomes a key battleground for drugmakers, looking to grab a slice of the burgeoning weight-loss treatment market, which some analysts predict will generate $150 billion a year or more by the en

See Full Page